Claim explorer · 60 reviews
Search every claim we have reviewed. Each verdict stays attached to its wording, evidence boundary, peptide, and full source-backed brief.
60 reviewed claims
Verdicts apply only to the exact wording shown.“Semaglutide is FDA-approved.”
Supported with scopeSome drug products containing semaglutide are FDA-approved for specific uses. The product, formulation, and indication matter.
“Compounded semaglutide is the same as an approved product.”
MisleadingFDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing.
“A result in one population proves the same benefit for everyone.”
Not establishedTrial population, endpoint, formulation, dose, duration, and indication define what a study can support.
“Insulin is an established treatment for diabetes.”
Supported with scopeMultiple insulin products are FDA-approved, and long-term human evidence supports insulin strategies in defined diabetes populations. The exact product and care context still matter.
“All insulin products work the same way and can be swapped freely.”
MisleadingInsulin products differ in timing, concentration, delivery system, and approved labeling. A switch can require clinical oversight and product-specific instructions.
“More intensive insulin treatment is always better.”
MisleadingThe DCCT found important complication reductions alongside substantially more severe hypoglycemia. Treatment intensity must be individualized and monitored.
“Tirzepatide has established human outcome evidence for defined metabolic indications.”
Supported with scopeApproved product labels and large randomized trials support specific glycemic and weight outcomes in defined populations.
“Trial results prove tirzepatide works the same way for everyone and should be used indefinitely.”
Not establishedTrials estimate effects for studied populations and durations. They do not establish an identical individual response or a universal treatment duration.
“Compounded tirzepatide is equivalent to an approved product.”
MisleadingFDA does not review compounded drugs for safety, effectiveness, or quality before marketing, so evidence for an approved product cannot simply be transferred.
“BPC-157 improves tendon healing in preclinical models.”
Supported with scopeCell and rat tendon studies report positive healing signals. The scope matters: these results support biological plausibility, not a proven human treatment.
“BPC-157 heals tendons and muscles in people.”
Not establishedEarly human work is too small and limited to establish efficacy. Reliable, replicated human outcome evidence is still needed.
“Athletes can use it because it is not a steroid.”
MisleadingWADA lists BPC-157 under S0 non-approved substances, prohibited at all times for covered athletes.
“CJC-1295 can raise GH and IGF-1 in healthy adults.”
Supported with scopeRandomized human studies reported sustained hormone increases. This supports a biomarker effect, not a patient benefit.
“CJC-1295 builds muscle and burns fat in people.”
Not establishedThe identified trials were not designed to establish durable improvements in body composition or function.
“All products called CJC-1295 are interchangeable.”
MisleadingThe literature and commercial market may refer to different molecular forms, salts, modifications, and combinations.
“Ipamorelin stimulates GH release in people.”
Supported with scopeA human dose-escalation study measured an episode of GH release. That is a pharmacodynamic effect.
“A GH response proves better recovery or body composition.”
Not establishedA biomarker response is not a clinical outcome, and the identified studies did not establish those benefits.
“Ipamorelin worked in its phase 2 surgical trial.”
MisleadingThe randomized trial reported no significant difference from placebo on its key and secondary efficacy analyses.
“Liraglutide has established human outcome evidence.”
Supported with scopeYes, for defined products, populations, indications, comparators, endpoints, and durations studied in major trials and reviewed labels.
“Every product sold as liraglutide is clinically equivalent.”
MisleadingApproved-product evidence includes product quality and labeling that cannot be assumed for every compounded or unapproved item.
“Cardiovascular trial results prove a universal longevity benefit.”
Not establishedLEADER tested a defined cardiovascular composite in a high-risk type 2 diabetes population, not lifespan extension in the general population.
“Retatrutide caused weight loss in a randomized human trial.”
Supported with scopeThe phase 2 trial reported dose-dependent weight reduction over 48 weeks in a defined adult population.
“Retatrutide is FDA-approved.”
MisleadingIt remains investigational. Positive trial results and sponsor announcements are not FDA marketing approval.
“Research retatrutide sold online is the same as clinical-trial material.”
Not establishedA matching label name does not establish sequence, purity, sterility, formulation, storage, or clinical equivalence.
“Tesamorelin reduces visceral fat in adults with HIV-associated lipodystrophy.”
Supported with scopePhase 3 trials and the product label support this outcome in the labeled population.
“Tesamorelin is an approved general weight-loss drug.”
MisleadingThe label specifically says it is not indicated for weight-loss management.
“Tesamorelin is permitted for competitive athletes.”
MisleadingThe 2026 WADA Prohibited List names tesamorelin.
“Sermorelin was once FDA-approved.”
Supported with scopeGeref approvals are documented. FDA later determined that the discontinued products were not withdrawn for reasons of safety or effectiveness.
“Sermorelin raises growth hormone, so it is proven to slow aging.”
MisleadingA hormone response is not a patient-centered aging or longevity outcome.
“Compounded sermorelin is an FDA-approved Geref generic.”
MisleadingThe historical product record does not make current compounded products approved or equivalent.
“TB-500 is the same thing as thymosin beta-4.”
MisleadingFDA describes TB-500 as a seven-amino-acid fragment of the much larger thymosin beta-4 molecule.
“TB-500 accelerates tendon and muscle healing in people.”
Not establishedThe FDA evidence review did not identify adequate human outcome evidence for wound-healing use.
“TB-500 is allowed in tested sport.”
MisleadingTB-500 is named on the current WADA Prohibited List.
“GHK-Cu has been studied in people.”
Supported with scopeYes, but the cited topical trial had 13 completers, found no significant objective improvement in erythema, wrinkles, or skin quality, and reported higher patient satisfaction. It does not establish broader outcomes or other routes.
“Topical GHK-Cu evidence proves injectable GHK-Cu works systemically.”
MisleadingRoute, formulation, exposure, product quality, and endpoint differ. Evidence cannot be transferred by ingredient name alone.
“Injectable GHK-Cu is proven safe.”
Not establishedFDA identifies limited human data and potential immunogenicity related to aggregation and peptide impurities.
“MOTS-c has promising metabolic effects in animal research.”
Supported with scopePreclinical metabolic findings are a real research signal, but they remain preclinical.
“MOTS-c produces weight loss in people.”
Not establishedFDA found no published human drug-product administration studies in its 2026 review.
“A UNII number means MOTS-c is FDA-approved.”
MisleadingFDA's substance registry explicitly states that UNII availability does not imply regulatory review or approval.
“AOD-9604 has been given to people in clinical studies.”
Supported with scopeFDA's review describes several human studies, primarily using oral or intravenous routes.
“Human exposure proves AOD-9604 is an effective fat-loss drug.”
MisleadingExposure and tolerability data do not establish a clinically meaningful weight-loss outcome.
“Injectable AOD-9604 has a well-characterized safety profile.”
Not establishedFDA identifies limited safety data, immunogenicity concerns, and missing information for proposed injectable use.
“Epitalon changes telomere biology in human cell lines.”
Supported with scopeA 2025 laboratory study reported telomere-length effects in cultured human cell lines.
“Epitalon is proven to treat insomnia.”
Not establishedFDA did not identify clinical insomnia studies of the nominated epitalon substances by the proposed route.
“Epitalon has been proven to extend human lifespan.”
Not establishedThe evidence does not provide reliable product-specific randomized lifespan outcomes for epitalon.
“Bremelanotide is FDA-approved for a specific form of HSDD.”
Supported with scopeVyleesi is approved for acquired, generalized HSDD in certain premenopausal women after specified exclusions.
“PT-141 is an approved sexual-performance enhancer for anyone.”
MisleadingThe label explicitly says the product is not for enhancing sexual performance and is not indicated for men or postmenopausal women.
“Compounded PT-141 has the same evidence as Vyleesi.”
Not establishedThe trial and approval record are product-specific and do not establish equivalence for compounded material.
“Afamelanotide increases pain-free light exposure in adults with EPP.”
Supported with scopeThe label and randomized trials support this defined rare-disease outcome.
“Scenesse is an approved cosmetic tanning implant.”
MisleadingIts approval is for pain-free light exposure in adults with EPP, not cosmetic tanning.
“Afamelanotide evidence proves other tanning peptides are safe and effective.”
MisleadingDifferent molecules and products require their own identity, quality, safety, and outcome evidence.
“Teriparatide reduces fracture risk in defined osteoporosis populations.”
Supported with scopeThe pivotal evidence and label support vertebral and nonvertebral fracture-risk reduction in studied high-risk populations.
“Teriparatide is proven to heal every fracture faster.”
Not establishedFracture prevention and acute fracture healing are different endpoints, and trial results vary by fracture setting.
“Because teriparatide is a peptide, it has no serious risks.”
MisleadingThe current label includes clinically important warnings, precautions, and population restrictions.
“Abaloparatide reduced fractures in a randomized phase 3 trial.”
Supported with scopeACTIVE found fewer new vertebral and nonvertebral fractures versus placebo in postmenopausal women with osteoporosis.
“Abaloparatide is proven to improve bone outcomes in every population.”
Not establishedApproved indications and trial populations define the evidence boundary.
“An anabolic bone effect means abaloparatide is a safe performance enhancer.”
MisleadingA prescription osteoporosis benefit-risk assessment does not establish safe enhancement in healthy people.
“Teduglutide can reduce parenteral-support needs in short bowel syndrome.”
Supported with scopeControlled trials and the Gattex label support this outcome in dependent short-bowel-syndrome populations.
“Teduglutide is a general gut-healing peptide.”
MisleadingThe approved indication and outcome are specific to short bowel syndrome with parenteral-support dependence.
“Because teduglutide promotes intestinal growth, it is low risk.”
MisleadingThe same biological activity underlies important warnings, including potential acceleration of neoplastic growth.
Why wording matters
“Changes a marker” may be supported while “improves recovery” remains unproven. We preserve that distinction instead of grading an entire molecule with one sweeping score.